From bench-side to bedside, Enexa is accelerating the time between molecular compositional analysis to clinical trials with our Parallel Pace™ process, aimed at producing real-world evidence in a fraction of the time.

The current drug development and trial cycle is slow and inefficient, relying on outdated protocols, and outsourced work compensated in terms of time spent and not incentivizing time to outcomes. There is a lack of understanding, funding, and support for the critical preclinical and clinical work that aids in bringing plant-based medicines to market.

Enexa seeks to normalize plant compounds as we bridge the gap between naturopathic preparations and the traditional medical space. Our Parallel Pace™, Investigational New Drug (IND) enabling, preclinical process relies on the principles of Translational Science, where our proprietary process takes the client from discovery, through cell and animal studies, all the way to clinical trial protocol identification and connection with our institutional research partners. By leveraging data sharing, dual path testing, and time-based milestones, Enexa is facilitating the next generation of plant-based medicines.